CELL INTELLIGENCE · 肿瘤细胞治疗研究

Monoclonal gammopathies encompass a continuous spectrum of clonal plasma-cell disorders ranging from indolent precursor states, such as MGUS and SMM, to overt multiple myeloma (MM), each distinguished by its biological complexity, clinical course, and therapeutic implications. Recent advances in molecular diagnostics and immune-based therapies have transformed disease management from empirical observation to precision-guided care. Highly sensitive techniques, such as mass spectrometry for M-protein detection, next-generation flow cytometry and sequencing for minimal residual disease (MRD), PET-CT imaging, and circulating tumor cell assays, have enabled earlier and more accurate detection of subclinical disease and treatment response. MRD negativity has emerged as a powerful prognostic and predictive marker, correlating strongly with prolonged progression-free and overall survival.

Parallel insights into clonal evolution, epigenetic remodeling, and microenvironmental influences, including hypoxia, cytokine networks, and stromal adhesion, have deepened understanding of resistance and relapse mechanisms. Therapeutically, the development of T-cell-redirecting immunotherapies, especially BCMA-directed CAR-T cells, bispecific antibodies, and emerging dual-antigen or "off-the-shelf" platforms, has achieved unprecedented response depth.

Nonetheless, major challenges remain, including standardization of MRD methodologies, the validation of MRD as a regulatory endpoint, management of CAR-T-related toxicities, and overcoming economic, logistical, and geographic barriers that limit equitable access to advanced therapies. Addressing these challenges will be essential to translating molecular precision and cellular innovation into durable remission and, ultimately, a functional cure for multiple myeloma.